Slagle Financial LLC Has $2.03 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Slagle Financial LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 4.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,028 shares of the company’s stock after acquiring an additional 644 shares during the period. Slagle Financial LLC’s holdings in Johnson & Johnson were worth $2,029,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of JNJ. denkapparat Operations GmbH bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $911,000. Pictet Asset Management Holding SA lifted its holdings in shares of Johnson & Johnson by 12.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,422,482 shares of the company’s stock worth $205,719,000 after purchasing an additional 155,308 shares in the last quarter. Broadway Wealth Solutions Inc. purchased a new position in Johnson & Johnson during the 4th quarter worth $419,000. New Age Alpha Advisors LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $665,000. Finally, Easterly Investment Partners LLC grew its stake in Johnson & Johnson by 3.6% in the 4th quarter. Easterly Investment Partners LLC now owns 91,814 shares of the company’s stock valued at $13,278,000 after buying an additional 3,164 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $163.22 on Friday. The stock has a 50 day moving average price of $158.35 and a two-hundred day moving average price of $156.23. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The firm has a market capitalization of $393.33 billion, a P/E ratio of 24.54, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period last year, the firm posted $2.29 earnings per share. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.04%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on JNJ. Citigroup cut their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Wells Fargo & Company decreased their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Leerink Partners dropped their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 19th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.